Stock price when the opinion was issued
Worth taking a good, hard look at. Phenomenal yield, and he likes yield. Chart is starting to form a bit of a bottom. Low PE. Has things in the pipeline that the market's not paying for. If you're a longer-term investor, well worth sitting on it and getting rewarded while you wait for an upside pop from the drugs coming through as hoped.
He's looking at it closely.
Organic growth in large cap pharmaceutical companies is something like 2%-3% and in order to offset that, they sell non-core assets and put that money back in their pipeline. This company’s pipeline has Prevnar which they are going to use in adults, as well as a breast cancer drug. These 2 drugs combined he feels are somewhere in the $2 billion range over the next couple of years. Feels the stock is worth $35-$36 on an analysis basis. Yield of 3.25%.